Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
[(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) is currently the most accurate and reliable tool for the assessment of response in Hodgkin's lymphoma (HL). FDG-PET is superior to conventional imaging techniques for detection of residual disease at the end of treatment, especially in the presence of a residual mass, a frequent finding in HL. FDG-PET response assessment has also a high predictive value early after the initiation of therapy. However, whether risk-adapted treatment strategies based on FDG-PET may also improve patient outcome remains to be proved.
Brepoels
Lieselot
L
Division of Nuclear Medicine, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. lieselot.brepoels@uz.kuleuven.be
Stroobants
Sigrid
S
D004307:Dose-Response Relationship, Radiation; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals; D012074:Remission Induction / Q000379:methods
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18